Key facts
- This page summarizes Daewoong Co., Ltd's Form 3 filing for AEON Biopharma, Inc. (AEON).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 29 Jan 2026, 21:25.
Daewoong Co., Ltd - 21 Jan 2026 Form 3 Insider Report for AEON Biopharma, Inc. (AEON)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- AEON
- Reported as of
- 21 Jan 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 29 Jan 2026, 21:25:12 UTC
- Prior SEC filing
- 16 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- Daewoong Co., Ltd., By: /s/ Kyu Sung Lim, Authorized Signatory
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Daewoong Co., Ltd filed Form 3 for AEON Biopharma, Inc. (AEON) on 29 Jan 2026.
Change
- Previous filing in this sequence was filed on 16 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001985493
Primary reporting owner
Daewoong Co., Ltd
- Relationship
- 10%+ Owner
- Address
- 244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO, KOREA, REPUBLIC OF
- Signature
- Daewoong Co., Ltd., By: /s/ Kyu Sung Lim, Authorized Signatory
- Signature date
- 23 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AEON
holding
Common Stock, $0.0001 par value per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 58,023
- Date
- 21 Jan 2026
- Ownership
- Direct
AEON
holding
Common Stock, $0.0001 par value per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,951,714
- Date
- 21 Jan 2026
- Ownership
- Indirect Beneficial Ownership in the 11,951,714 owned by Daewoong Pharmaceutical Co., Ltd
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AEON
holding
Derivative
Senior Secured Convertible Note
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 21 Jan 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- $1,500,000
- Exercise price
- Footnotes
- F1, F2, F3
AEON
holding
Derivative
Pre-Funded Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 21 Jan 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 11,236,631
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F3, F4
AEON
holding
Derivative
Common Stock Warrant
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 21 Jan 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 8,000,000
- Exercise price
- $1.09
- Footnotes
- F1, F2, F3, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Daewoong Co., Ltd. ("DWC"), a company organized under the laws of the Republic of Korea, owns 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. ("DWP"), a company organized under the laws of the Republic of Korea; DWC has voting and dispositive power over the securities held by DWP and, therefore, may be deemed to beneficially own such securities indirectly.
Footnote F2
As previously disclosed on January 21, 2026, upon completion by AEON Biopharma Inc. (the "Company") of a bona-fide third-party financing for aggregate gross cash proceeds to the Company of at least $30.0 million (a "Qualified Financing"), the convertible notes shall automatically convert into a number of shares of Common Stock or Pre-Funded Warrants equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the convertible notes and all accrued and unpaid interest to be converted divided by (b) the per share price of the common stock sold in the Qualified Financing, and warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share (the "Common Stock Warrant"), resulting in DWP beneficially owning more than 10% of the Issuer's outstanding Common Stock.
Footnote F3
(continued from footnote [2]). As a result, DWC beneficially owns an aggregate of (i) 12,009,737 shares of Common Stock (including shares previously held). In addition, DWP received (ii) the New Convertible Note in the principal amount of $1,500,000, (iii) the Pre-Funded Warrants to purchase up to 11,236,631 shares of Common Stock, and (iv) the Common Stock Warrant to purchase up to 8,000,000 shares of Common Stock. DWC may be deemed to beneficially own indirectly the securities described in clauses (ii) through (iv) held by DWP.
Footnote F4
The Pre-Funded Warrant is exercisable on or after the Original Issue Date and does not expire until exercised in full.
Footnote F5
The Common Stock Warrant is exercisable on or after the Initial Exercise Date and expires at 5:00 p.m. (New York City time) on the Termination Date, as defined in the form of warrant filed as Exhibit 4.2 to the Company's Form 8-K filed with the SEC on November 12, 2025.